2.29
-0.08(-3.38%)
Currency In USD
| Previous Close | 2.37 |
| Open | 2.34 |
| Day High | 2.39 |
| Day Low | 2.29 |
| 52-Week High | 3.6 |
| 52-Week Low | 1 |
| Volume | 298,417 |
| Average Volume | 536,109 |
| Market Cap | 138.71M |
| PE | -1.24 |
| EPS | -1.85 |
| Moving Average 50 Days | 2.52 |
| Moving Average 200 Days | 2.18 |
| Change | -0.08 |
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
GlobeNewswire Inc.
Mar 10, 2026 8:00 PM GMT
NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheim
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheime